Urinary Urinary Nerve Growth Factor (NGF) as a Biomarker for Mixed Urinary Incontinence

Inclusion Criteria: * Women aged 18 or over 18 years with MUI for 3 or over 3 months * Proven SUI by urodynamic study (UDS)or stress test * Abdominal leak point pressure (ALPP)of 120 or less than 120cmH2O in UDS * Symptoms verified using 5 day bladder diary as below i) number of urgency incontinence; 3 or more than 3/5days ii) number of micturition; 8 or more than 8/24hrs iii) number of urgency; 2 or more than 2/24hrs * Women who cannot be pregnant or do not have plan to be pregnant * Ability and willingness to correctly complete the micturition diary and questionnaire * Capable of understanding and having signed the informed consent form after full discussion of the research nature of the treatment and its risks and benefits Exclusion Criteria: * The subject has WBC≧3, Albumin≧+1, Nit ≧+1 upon urinalysis * On an unstable dosage of any drug with anticholinergic side effects, or expected to start such treatment during the study * Patient has a significant pelvic orgen prolapse (POP) of ICS Stage 3 or over 3. * Patients with combined POP surgery. * Patients with bladder outlet obstruction on UDS or physical exam * Patients with detrusor underactivity * Diagnosed or suspected interstitial cystitis or bladder cancer * History of radiation therapy on pelvic cavity * Patients with neurologic condition which can affect lower urinary tract function * History of urogenical malignancy within recent 2 years * Treatment within the 14 days preceding enrollment, or expected to initiate treatment during the study with: i)Any anticholinergic drugs and any drug treatment affecting lower urinary tract function Estrogen treatment started more than 2 months prior to inclusion is allowed. ii) electrostimulation, bladder training, electromagnetic treatment * Patient is on anti-coagulation therapy. * Any other condition which, in the opinion of the investigator, makes the patient unsuitable for inclusion